ArticleJournal of pharmacy & bioallied sciences2025
A Randomized Controlled Study Comparing Albumin-Enriched Platelet-Rich Fibrin and Conventional Platelet-Rich Fibrin for the Treatment of Intrabony Defects.
Article in Journal of pharmacy & bioallied sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Trial
- Clinical effectiveness of albumin-enriched platelet-rich fibrin (Alb-PRF) in periodontal and peri-implant regenerative surgery: a systematic review.Odontology · 2026Review
- Next-generation platelet concentrate: Alb-PRF outperformed PRP and H-PRF in promoting endothelial function and wound healing.Scientific reports · 2026Article
- Comparative assessment of injectable platelet-rich fibrin versus concentrated growth factor for periodontal intrabony defects.Bioinformation · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The treatment of intrabony defects (IBDs) is a significant challenge in periodontal therapy, with regenerative approaches like platelet concentrates showing promising outcomes. Materials and Methods: A randomized controlled study was conducted on 20 IBDs from patients who met the inclusion criteria. After Phase I therapy, the defects were randomly assigned to two groups: Results: Both groups showed significant improvement in clinical parameters after one month. In Group I, the mean PPD reduction was 3.2 mm, and CAL gain was 2.8 mm, while in Group II, PPD reduction was 2.9 mm, and CAL gain was 2.5 mm. The reduction in BOP was 50% in Group I and 45% in Group II. PI improvement was similar across groups. Alb-PRF demonstrated a marginally better performance in all clinical parameters compared to PRF alone. Conclusion: Alb-PRF, as an adjunct to OFD, showed better outcomes in reducing PPD and gaining CAL compared to PRF. The results suggest that Alb-PRF may provide a superior regenerative effect in managing IBDs over a short-term period.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.